How A Biomarker Revived Synta’s Cancer Drug Elesclomol
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Using a simple, cheap, available enzyme test, Synta Pharmaceuticals Corp. has been able to rescue the development program for its oncology candidate elesclomol after a high-profile Phase III failure in melanoma.